TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20083961

Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study: 17340137

Group type: EXPERIMENTAL
Intervention: MDR1 and BCRP mRNA expression
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Higher BCRP mRNA
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: CD34-related MDR1/BCRP coexpression
Number of subjects: 154
Study: 16256784

Group type: EXPERIMENTAL
Intervention: Insulin treatment during cardiopulmonary bypass
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo treatment during cardiopulmonary bypass
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 381
Study: 11867394

Group type: EXPERIMENTAL
Intervention: Trachlight
Number of subjects: 148

Group type: COMPARATOR
Intervention: Fastrach
Number of subjects: 148
Study: 10218737

Group type: EXPERIMENTAL
Intervention: Mibefradil (50 mg, titrated to 100 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Enalapril (20 mg, titrated to 2 x 20 mg)
Number of subjects: 48
Study: 8730975

Group type: EXPERIMENTAL
Intervention: Allopurinol 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Allopurinol 100 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Allopurinol 600 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Allopurinol 900 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhibition of xanthine oxidase
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1MU/1MX ratio
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oxypurinol concentration for inhibition of xanthine oxidase
Number of subjects: 8
Study: 1858727

Group type: EXPERIMENTAL
Intervention: H influenzae b oligosaccharide‐CRM197 conjugate vaccine (3 doses)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: H influenzae b oligosaccharide‐CRM197 conjugate vaccine (2 doses) followed by H influenzae type b polysaccharide vaccine (1 dose)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: H influenzae b oligosaccharide‐CRM197 conjugate vaccine (1 dose) followed by H influenzae type b polysaccharide vaccine (2 doses)
Number of subjects: 171

Group type: COMPARATOR
Intervention: H influenzae type b polysaccharide vaccine (as a second dose)
Number of subjects: 171
Study: 6354385

Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 23
Study: 30794252

Group type: EXPERIMENTAL
Intervention: Microtextured implants with microgrooved collar design
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Narrow implant diameter
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Overall implant survival
Number of subjects: 58
Study: 28129499

Group type: EXPERIMENTAL
Intervention: Therapeutic Education System
Number of subjects: 507

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 507
Study: 25393645

Group type: EXPERIMENTAL
Intervention: Abaloparatide 20 μg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Abaloparatide 40 μg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Abaloparatide 80 μg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 22383279

Group type: EXPERIMENTAL
Intervention: Stress management training (SMT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Regular care condition (Control)
Number of subjects: 70
Study: 21855560

Group type: EXPERIMENTAL
Intervention: Active rTMS over the left dorsolateral prefrontal cortex (LDLPFC) using 10-Hz pulses for 5- and 20-s intertrain intervals
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham rTMS over the left dorsolateral prefrontal cortex (LDLPFC)
Number of subjects: 90
Study: 19860834

Group type: EXPERIMENTAL
Intervention: apoNgb at pH 2.0
Number of subjects: 0

Group type: COMPARATOR
Intervention: apoMb at pH 2.0
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ngb
Number of subjects: 0
Study: 16499744

Group type: EXPERIMENTAL
Intervention: Nurse-directed care (NC) group
Number of subjects: 23

Group type: COMPARATOR
Intervention: Routine care (RC) group
Number of subjects: 23
Study: 14767164

Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 16

Group type: COMPARATOR
Intervention: Manual cross-brushing technique
Number of subjects: 16
Study: 11704092

Group type: EXPERIMENTAL
Intervention: EE20/GSD75
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: EE15/GSD60
Number of subjects: 18
Study: 1316100

Group type: EXPERIMENTAL
Intervention: Tegafur.Uracil (UFT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Tegafur (FT)
Number of subjects: 90
Study: 3914885

Group type: EXPERIMENTAL
Intervention: Intravaginal PGF2 alpha (40 mg in tylose gel)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Intravaginal PGF2 alpha
Number of subjects: 202

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 202
Study: 29857776

Group type: EXPERIMENTAL
Intervention: Diabetes education plus eight group sessions of stress management and relaxation (DE + SMR)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Diabetes education only (DE-only)
Number of subjects: 55
Study: 27577237

Group type: EXPERIMENTAL
Intervention: PfAMA1-FVO vaccine (50 µg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control vaccine (tetanus toxoid)
Number of subjects: 40
Study: 24388792

Group type: EXPERIMENTAL
Intervention: One-day bowel preparation (fiber-free diet and 3 L of polyethylene glycol on day 0)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Two-day bowel preparation (liquid diet and 3 L of polyethylene glycol in the evening of day -1, and 1L of PEG in the early morning of day 0)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: One-day bowel preparation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Two-day bowel preparation
Number of subjects: 40
Study: 22139886

Group type: EXPERIMENTAL
Intervention: PVI + ablation of non-PV triggers (arm 1)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: PVI + ablation of non-PV triggers + empirical ablation at common non-PV AF trigger sites (arm 2)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: PVI + ablation of non-PV triggers + ablation of left atrial complex fractionated electrogram sites (arm 3)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard approach (PVI)
Number of subjects: 156
Study: 20544810

Group type: EXPERIMENTAL
Intervention: 1.5 mg pramipexole
Number of subjects: 535

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study: 18164462

Group type: EXPERIMENTAL
Intervention: Various nonsurgical interventions for CLBP; specific interventions not detailed.
Number of subjects: 0
Study: 16168344

Group type: EXPERIMENTAL
Intervention: Intensive follow-up (n=218), with questionnaires sent 1, 6, and 12 months after screening
Number of subjects: 431

Group type: COMPARATOR
Intervention: Limited follow-up (n=213), with a single questionnaire at 1 year
Number of subjects: 431
Study: 12663319

Group type: EXPERIMENTAL
Intervention: Intervention group (tailored nutrition counseling)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 10719133

Group type: EXPERIMENTAL
Intervention: Blood pressure biofeedback treatment (BF) once a week for a total of four sessions
Number of subjects: 38

Group type: COMPARATOR
Intervention: Blood pressure biofeedback treatment (BF)
Number of subjects: 38
Study: 8646865

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate cream, 0.05%, twice-daily (BID) application
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate cream, 0.05%, once-daily (QD) application
Number of subjects: 238

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 238
Study: 1906692

Group type: EXPERIMENTAL
Intervention: Invasive strategy (coronary arteriography with percutaneous angioplasty if feasible)
Number of subjects: 3339

Group type: EXPERIMENTAL
Intervention: 150 mg rt-PA
Number of subjects: 3339

Group type: EXPERIMENTAL
Intervention: Immediate intravenous beta-blocker therapy
Number of subjects: 3339

Group type: COMPARATOR
Intervention: 100 mg rt-PA
Number of subjects: 3339

Group type: COMPARATOR
Intervention: Conservative strategy (coronary arteriography for recurrent ischemia)
Number of subjects: 3339
Study: 3994783

Group type: EXPERIMENTAL
Intervention: Ciprofibrate (100 mg daily, single administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fenofibrate (300 mg daily, 3 administrations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciprofibrate (100 or 200 mg/day after 9 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fenofibrate (400 mg/day after 9 months)
Number of subjects: 0
Study: 29910048

Group type: EXPERIMENTAL
Intervention: Discharged event-free on day 3 (1,689 patients)
Number of subjects: 20410

Group type: COMPARATOR
Intervention: Remained hospitalized at the end of day 3 (14,190 patients)
Number of subjects: 20410

Group type: EXPERIMENTAL
Intervention: Discharged event-free on day 4 (1,706 patients)
Number of subjects: 20410

Group type: COMPARATOR
Intervention: Remained hospitalized at the end of day 4 (11,628 patients)
Number of subjects: 20410
Study: 26415029

Group type: EXPERIMENTAL
Intervention: Immediate skin‐to‐skin contact (ISSC) and breastfeeding in the operating room during cesarean section (C/S)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Breastfeeding 1 hour after cesarean section (C/S)
Number of subjects: 90
Study: 24852255

Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT) for 8 weeks, 1 day per week, 60-minute session duration
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no additional conditioning training)
Number of subjects: 18
Study: 22339105

Group type: EXPERIMENTAL
Intervention: Far infrared rays (FIR) thermal therapy applied on acupoints ST37, ST38, ST39, ST40 from day 3 to day 5 post-surgery
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 41
Study: 21519296

Group type: EXPERIMENTAL
Intervention: IV 3% hypertonic saline (HTS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral 3% hypertonic saline (HTS)
Number of subjects: 8
Study: 18642381

Group type: EXPERIMENTAL
Intervention: Electrical stimulation-supported voice exercises (ES)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Voice exercise therapy (VE)
Number of subjects: 90
Study: 16926331

Group type: EXPERIMENTAL
Intervention: Endovascular brachytherapy (EBT) with an iridium 192 source, prescribed dose of 12 Gy at 3 mm from the source axis
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA) plus EBT
Number of subjects: 102

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA) alone
Number of subjects: 102
Study: 12907320

Group type: EXPERIMENTAL
Intervention: Graded balloon distentions at the striated muscle segment
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Graded balloon distentions at the smooth muscle segment
Number of subjects: 22
Study: 11041310

Group type: EXPERIMENTAL
Intervention: Intravenous heroin
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Oral opiates
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Mixed regimens (intravenous heroin and oral opiates)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Heroin maintenance
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Alternative treatments (methadone maintenance, detoxification)
Number of subjects: 37
Study: 8752162

Group type: EXPERIMENTAL
Intervention: r‐TNF‐alpha and melphalan
Number of subjects: 24

Group type: COMPARATOR
Intervention: melphalan only (control)
Number of subjects: 24
Study: 1418021

Group type: EXPERIMENTAL
Intervention: Intraarticular injections of glycosaminoglycan polysulfate (GAGPS) plus basic conservative treatment
Number of subjects: 53

Group type: COMPARATOR
Intervention: Physiologic saline injections plus basic conservative treatment
Number of subjects: 53

Group type: COMPARATOR
Intervention: Basic conservative treatment alone (6-week program of quadriceps muscle exercise, elimination of symptom-producing activities, and oral NSAIDs)
Number of subjects: 53
Study: 6323185

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 25
Study: 30700349

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted phacoemulsification
Number of subjects: 94

Group type: COMPARATOR
Intervention: Traditional phacoemulsification
Number of subjects: 94
Study: 29733908

Group type: EXPERIMENTAL
Intervention: PET scan staging (Yes)
Number of subjects: 598

Group type: COMPARATOR
Intervention: Conventional staging (No)
Number of subjects: 598
Study: 26602795

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Saphenofemoral ligation and stripping (SFL/S)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both treatments (EVLA and SFL/S)
Number of subjects: 121
Study: 25062740

Group type: EXPERIMENTAL
Intervention: Miller blade lifting the epiglottis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MAC blade lifting the tongue base
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Miller blade lifting the tongue base
Number of subjects: 50
Study: 23206200

Group type: EXPERIMENTAL
Intervention: COMPAS intervention (five-session behavioral intervention)
Number of subjects: 827

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 827
Study: 20197703

Group type: EXPERIMENTAL
Intervention: Higher fasting insulin levels
Number of subjects: 1353

Group type: EXPERIMENTAL
Intervention: Higher C-peptide levels
Number of subjects: 1353
Study: 17656271

Group type: EXPERIMENTAL
Intervention: Mepivacaine (30 mg in 1 mL saline)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combination of Mepivacaine and Morphine (30 mg mepivacaine and 1 mg morphine in 1 mL saline)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Morphine (1 mg in 1 mL saline)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline control (1 mL saline)
Number of subjects: 35
Study: 16049199

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 80
Study: 11860043

Group type: EXPERIMENTAL
Intervention: Pennebaker writing task
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-essay control conditions
Number of subjects: 0
Study: 12811865

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7758179

Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 200 mg IM given twice, 2 weeks apart
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 16
Study: 2321713

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of lytic cocktail (0.05 ml/kg, max 2.0 ml)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rectal administration of lytic cocktail (0.07 ml/kg, max 2.8 ml)
Number of subjects: 51
Study: 6968567

Group type: EXPERIMENTAL
Intervention: ICI 35 868, dose: 2 mg kg‐1, injected over 30 s
Number of subjects: 10

Group type: COMPARATOR
Intervention: Althesin, dose: 0.05 ml kg‐1, injected over 30 s
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ICI 35 868
Number of subjects: 10

Group type: COMPARATOR
Intervention: Althesin
Number of subjects: 10
Study: 31940991

Group type: EXPERIMENTAL
Intervention: Paclitaxel-based chemotherapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Non-paclitaxel-based chemotherapy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Laparoscopy for histological confirmation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Complete open staging surgery after laparoscopy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Positive washing cytology
Number of subjects: 88
Study: 30732143

Group type: EXPERIMENTAL
Intervention: Interactive voice response system (IVRS) providing automatic calls in 3 categories: educational, medication adherence, and reminders.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 120
Study: 27495950

Group type: EXPERIMENTAL
Intervention: e‐reader iPAD
Number of subjects: 44

Group type: COMPARATOR
Intervention: print
Number of subjects: 44
Study: 25576240

Group type: EXPERIMENTAL
Intervention: Regular physical exercise for 6 months (group I)
Number of subjects: 64
Study: 23675422

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 21852281

Group type: EXPERIMENTAL
Intervention: Walking program (WG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 21
Study: 19450038

Group type: EXPERIMENTAL
Intervention: Social norms of sharing needles among friends who inject
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Social norms of sharing cookers among friends who inject
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Social norms of sharing cotton among friends who inject
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Norms of sharing needles and front- or back-loading among friends who inject
Number of subjects: 933
Study: 16470234

Group type: EXPERIMENTAL
Intervention: Risk-counseling intervention
Number of subjects: 267

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 267
Study: 12847161

Group type: EXPERIMENTAL
Intervention: Patients with left ATL
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Patients with right ATL
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Patients with left TLE
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Patients with right TLE
Number of subjects: 63

Group type: COMPARATOR
Intervention: Healthy age- and education-matched controls
Number of subjects: 63
Study: 10841953

Group type: EXPERIMENTAL
Intervention: Microbipolar dissection (MBPD)
Number of subjects: 200
Study: 9322987

Group type: EXPERIMENTAL
Intervention: Aspirin, 100 mg/d, starting at 12 to 16 weeks of gestation, taken at time 1 (on awakening)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aspirin, 100 mg/d, starting at 12 to 16 weeks of gestation, taken at time 2 (8 hours after awakening)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aspirin, 100 mg/d, starting at 12 to 16 weeks of gestation, taken at time 3 (before bedtime)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7679668

Group type: EXPERIMENTAL
Intervention: Rest interval of 2 weeks
Number of subjects: 284

Group type: COMPARATOR
Intervention: Rest interval of 4 weeks
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Patients completing all three courses
Number of subjects: 284

Group type: COMPARATOR
Intervention: Patients completing less than three courses
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Patients with Karnofsky Performance Status >= 80 and 2 week interval
Number of subjects: 284

Group type: COMPARATOR
Intervention: Patients with Karnofsky Performance Status >= 80 and 4 week interval
Number of subjects: 284
Study: 2942203

Group type: EXPERIMENTAL
Intervention: Tamoxifen 30 mg per day alternating every two weeks with medroxyprogesterone acetate (MPA) 1,000 mg per day orally.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Tamoxifen 30 mg per day and after relapse, high dosage of MPA alone.
Number of subjects: 64
Study: 31729107

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10128
Study: 29726596

Group type: EXPERIMENTAL
Intervention: Intraprocedural thrombotic events (IPTE)
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: ACUITY minor bleeding
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: ACUITY major bleeding
Number of subjects: 1171
Study: 27941712

Group type: EXPERIMENTAL
Intervention: Treadmill training with visual biofeedback
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treadmill training without visual biofeedback (Control)
Number of subjects: 30
Study: 25192980

Group type: EXPERIMENTAL
Intervention: Active rTMS combined with active venlafaxine (150‐225 mg/day)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Active rTMS combined with placebo venlafaxine
Number of subjects: 170

Group type: COMPARATOR
Intervention: Sham rTMS combined with active venlafaxine (150‐225 mg/day)
Number of subjects: 170
Study: 22411689

Group type: EXPERIMENTAL
Intervention: DGLA-enriched oil (450 mg as free DGLA) for 4 weeks
Number of subjects: 0
Study: 20865880

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control
Number of subjects: 130
Study: 18179510

Group type: EXPERIMENTAL
Intervention: Paired modeling
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Positive reinforcement
Number of subjects: 15

Group type: COMPARATOR
Intervention: Close supervisor's position
Number of subjects: 15

Group type: COMPARATOR
Intervention: Distant supervisor's position
Number of subjects: 15
Study: 15086645

Group type: EXPERIMENTAL
Intervention: APN-directed discharge planning and home follow-up protocol (3 months)
Number of subjects: 239
Study: 11949798

Group type: EXPERIMENTAL
Intervention: Scotchbond 1 (dentin bonding agent)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MS Coat (resin emulsion)
Number of subjects: 20
Study: 9490250

Group type: EXPERIMENTAL
Intervention: Surgical treatment for Dupuytren contracture
Number of subjects: 47
Study: 8004601

Group type: EXPERIMENTAL
Intervention: Mammography alone
Number of subjects: 4051

Group type: EXPERIMENTAL
Intervention: Physical examination and mammography
Number of subjects: 4051

Group type: EXPERIMENTAL
Intervention: Tumor size <5 cm or no positive lymph nodes
Number of subjects: 4051

Group type: EXPERIMENTAL
Intervention: Large tumors (≥5 cm)
Number of subjects: 4051
Study: 3223639

Group type: EXPERIMENTAL
Intervention: 100 micrograms.kg-1 morphine (group M)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 6.6 micrograms.kg-1 buprenorphine (group B)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.1 ml.kg-1 normal saline placebo (group T)
Number of subjects: 24
Study: 30115911

Group type: EXPERIMENTAL
Intervention: 400 mg valproate
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 200 mg pregabalin
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 28508107

Group type: EXPERIMENTAL
Intervention: Memantine add-on treatment
Number of subjects: 448